Clinical Evaluation of Therapy™ Cool Flex™ Irrigated Ablation System for the Treatment of Typical Atrial Flutter (FLEXION AFL)
To demonstrate that ablation with the Therapy™ Cool Flex™ Irrigated Ablation System is effective in the treatment of typical atrial flutter (cavo-tricuspid dependent) and that its use does not result in an unacceptable risk of intra-procedural, serious cardiac adverse events.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Clinical Evaluation of Therapy™ Cool Flex™ Irrigated Ablation System for the Treatment of Typical Atrial Flutter|
- Primary Safety [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]Primary safety is defined as the incidence of composite, serious adverse events within 7 days post-procedure, regardless of whether a determination can be made regarding device relatedness.
- Primary Efficacy / Acute Success [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]Primary efficacy / Acute success is defined as the ability to obtain bi-directional block in the cavo-tricuspid isthmus and noninducibility of typical atrial flutter at least 30 minutes following the last RF ablation with the Therapy™ Cool Flex™ Catheter Ablation System.
- Secondary Efficacy / Chronic Success [ Time Frame: 3 months ] [ Designated as safety issue: No ]Secondary efficacy / Chronic success is defined as freedom from the recurrence of typical atrial flutter 3 months post ablation. Flutter recurrence can be documented on an ECG (or similar such as Holter, telemetry, rhythm strips, etc.). Repeat ablations, new antiarrhythmia medication (Class Ia, Ic, or III) or increase in the dosage of existing anti-arrhythmia medication (Class 1a, 1c, III) during the 3 months post ablation are considered chronic failures.
|Study Start Date:||November 2011|
|Study Completion Date:||October 2012|
|Primary Completion Date:||June 2012 (Final data collection date for primary outcome measure)|
|Experimental: Treatment Arm||
Device: Therapy™ Cool Flex™ Irrigated Ablation System
The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:
This will be a prospective, multi-center and non-randomized study. All treated patients will receive ablation therapy for typical atrial flutter using the TherapyTM Cool FlexTM Irrigated Ablation System. Historical data from combined published (PMA P060019 Cool Path) and reported (IDE G090109 Cool Path Duo) Atrial Flutter studies will be used to determine performance goals for study endpoints.
Show 25 Study Locations
|Principal Investigator:||Raul Weiss, MD||Ohio State University|